| | | |
| Gain insight into leading CDMOs’ available capacity, capabilities, and timelines for biologic API development at the Large Molecule Drug Substance session of the Outsourced Pharma Capacity Update (Oct. 7). This virtual event highlights cell line development, fermentation, purification, and scale-up strategies — critical for producing high-quality biologics. Engage through short, interactive presentations and connect with CDMOs ready to support your pipeline needs. Open to biopharma companies, consultants, and investors seeking development and manufacturing partners. Save your spot today! |
|
| | | | | By J. Claud and R. Dormer, Hyman, Phelps, & McNamara | FDA Commissioner Marty Makary has promised to end the so-called "double standard" of announced overseas inspections. Does the agency have the resources? | |
|
| | A conversation with Bhanu Chandra Mulukutla, Pfizer | Researchers at Pfizer are developing a cell line that synthesizes these amino acids autonomously, which could reduce costs and increase stability. | |
|
| | |
|
|
